Our findings demonstrated a remarkably high predictive ability to forecast clinical efficacy in patients with advanced gastric cancer receiving anti-PD-1 mAb treatment, especially when IL-6, IL-8, and CEA are combined (AUC: 0.872), underscoring the robustness of these biomarkers. This evidence concerns the gene PDCD1 and gastric cancer.